These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

169 related articles for article (PubMed ID: 28801620)

  • 1. A Novel Aldosterone Antagonist Limits Renal Injury in 5/6 Nephrectomy.
    Fujihara CK; Kowala MC; Breyer MD; Sena CR; Rodrigues MV; Arias SCA; Fanelli C; Malheiros DM; Jadhav PK; Montrose-Rafizadeh C; Krieger JE; Zatz R
    Sci Rep; 2017 Aug; 7(1):7899. PubMed ID: 28801620
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Regression of albuminuria and hypertension and arrest of severe renal injury by a losartan-hydrochlorothiazide association in a model of very advanced nephropathy.
    Arias SC; Valente CP; Machado FG; Fanelli C; Origassa CS; de Brito T; Camara NO; Malheiros DM; Zatz R; Fujihara CK
    PLoS One; 2013; 8(2):e56215. PubMed ID: 23431367
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Losartan-hydrochlorothiazide association promotes lasting blood pressure normalization and completely arrests long-term renal injury in the 5/6 ablation model.
    Fujihara CK; Malheiros DM; Zatz R
    Am J Physiol Renal Physiol; 2007 Jun; 292(6):F1810-8. PubMed ID: 17344184
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Early brief treatment with losartan plus mycophenolate mofetil provides lasting renoprotection in a renal ablation model.
    Fujihara CK; Vieira JM; Sena CR; Ventura BH; Malheiros DM; Zatz R
    Am J Nephrol; 2010; 32(2):95-102. PubMed ID: 20551627
    [TBL] [Abstract][Full Text] [Related]  

  • 5. An extremely high dose of losartan affords superior renoprotection in the remnant model.
    Fujihara CK; Velho M; Malheiros DM; Zatz R
    Kidney Int; 2005 May; 67(5):1913-24. PubMed ID: 15840039
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Anti-albuminuric effect of the aldosterone blocker eplerenone in non-diabetic hypertensive patients with albuminuria: a double-blind, randomised, placebo-controlled trial.
    Ando K; Ohtsu H; Uchida S; Kaname S; Arakawa Y; Fujita T;
    Lancet Diabetes Endocrinol; 2014 Dec; 2(12):944-53. PubMed ID: 25466242
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Losartan and angiotensin II inhibit aldosterone production in anephric rats via different actions on the intraadrenal renin-angiotensin system.
    Peters J; Obermüller N; Woyth A; Peters B; Maser-Gluth C; Kränzlin B; Gretz N
    Endocrinology; 1999 Feb; 140(2):675-82. PubMed ID: 9927293
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Renal expression of COX-2, ANG II, and AT1 receptor in remnant kidney: strong renoprotection by therapy with losartan and a nonsteroidal anti-inflammatory.
    Gonçalves AR; Fujihara CK; Mattar AL; Malheiros DM; Noronha Ide L; de Nucci G; Zatz R
    Am J Physiol Renal Physiol; 2004 May; 286(5):F945-54. PubMed ID: 15075190
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Renin-angiotensin system blockade alone or combined with ET
    Sedláková L; Čertíková Chábová V; Doleželová Š; Škaroupková P; Kopkan L; Husková Z; Červenková L; Kikerlová S; Vaněčková I; Sadowski J; Kompanowska-Jezierska E; Kujal P; Kramer HJ; Červenka L
    Clin Exp Hypertens; 2017; 39(2):183-195. PubMed ID: 28287881
    [TBL] [Abstract][Full Text] [Related]  

  • 10. An association of losartan-hydrochlorothiazide, but not losartan-furosemide, completely arrests progressive injury in the remnant kidney.
    Arias SC; Souza RA; Malheiros DM; Fanelli C; Fujihara CK; Zatz R
    Am J Physiol Renal Physiol; 2016 Jan; 310(2):F135-43. PubMed ID: 26538442
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Effects of eplerenone versus losartan in patients with low-renin hypertension.
    Weinberger MH; White WB; Ruilope LM; MacDonald TM; Davidson RC; Roniker B; Patrick JL; Krause SL
    Am Heart J; 2005 Sep; 150(3):426-33. PubMed ID: 16169319
    [TBL] [Abstract][Full Text] [Related]  

  • 12. The effect of aldosterone and aldosterone blockade on the progression of chronic kidney disease: a randomized placebo-controlled clinical trial.
    Minakuchi H; Wakino S; Urai H; Kurokochi A; Hasegawa K; Kanda T; Tokuyama H; Itoh H
    Sci Rep; 2020 Oct; 10(1):16626. PubMed ID: 33024237
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Olmesartan combined with renal denervation reduces blood pressure in association with sympatho-inhibitory and aldosterone-reducing effects in hypertensive mice with chronic kidney disease.
    Nishihara M; Takesue K; Hirooka Y
    Clin Exp Hypertens; 2019; 41(3):211-219. PubMed ID: 29694249
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Eplerenone improves hyperglycemia and sympathetic excitation in chronic renocardiac syndrome in rats.
    Wu CJ; Li YH; Wu FZ; Chen HH
    Naunyn Schmiedebergs Arch Pharmacol; 2024 Feb; 397(2):1081-1092. PubMed ID: 37589737
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Effect of ACE2 and angiotensin-(1-7) in a mouse model of early chronic kidney disease.
    Dilauro M; Zimpelmann J; Robertson SJ; Genest D; Burns KD
    Am J Physiol Renal Physiol; 2010 Jun; 298(6):F1523-32. PubMed ID: 20357030
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Aldosterone blockade in chronic kidney disease.
    Hirsch JS; Drexler Y; Bomback AS
    Semin Nephrol; 2014 May; 34(3):307-22. PubMed ID: 25016401
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Treatment with enalapril and not diltiazem ameliorated progression of chronic kidney disease in rats, and normalized renal AT1 receptor expression as measured with PET imaging.
    Ismail B; deKemp RA; Croteau E; Hadizad T; Burns KD; Beanlands RS; DaSilva JN
    PLoS One; 2017; 12(5):e0177451. PubMed ID: 28542215
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Benefit of combination therapy with dapagliflozin and eplerenone on cardiac function and fibrosis in rats with non-diabetic chronic kidney disease.
    Soulié M; Stephan Y; Durand M; Lima-Posada I; Palacios-Ramírez R; Nicol L; Lopez-Andres N; Mulder P; Jaisser F
    Sci Rep; 2024 Oct; 14(1):23955. PubMed ID: 39397161
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Combined mycophenolate mofetil and losartan therapy arrests established injury in the remnant kidney.
    Fujihara CK; DE Lourdes Noronha I; Malheiros DMAC; Antunes GR; DE Oliveira IB; Zatz R
    J Am Soc Nephrol; 2000 Feb; 11(2):283-290. PubMed ID: 10665935
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Losartan protects mesenteric arteries from ROS-associated decrease in myogenic constriction following 5/6 nephrectomy.
    Vavrinec P; van Dokkum RP; Goris M; Buikema H; Henning RH
    J Renin Angiotensin Aldosterone Syst; 2011 Sep; 12(3):184-94. PubMed ID: 21393360
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 9.